inactivated poliovirus vaccine

Also found in: Dictionary, Thesaurus, Encyclopedia.

po·li·o·vi·rus vac·cines

1. inactivated poliovirus vaccine (IPV), an aqueous suspension of inactivated strains of poliomyelitis virus (types 1, 2, and 3) used by injection; has largely been replaced by the oral vaccine;
2. oral poliovirus vaccine (OPV), an aqueous suspension of live, attenuated strains of poliomyelitis virus (types 1, 2, and 3) given orally for active immunization against poliomyelitis.

inactivated poliovirus vaccine

, poliovirus vaccine, inactivated
An injectable vaccine made from three types of inactivated polioviruses. Developed by Jonas E. Salk, it was the first successful vaccine against poliomyelitis and is now the only polio vaccine administered in the U.S. Synonym: Salk vaccine

Infants should be given three doses, the first at 2 months of age, followed by two more doses at 8-week intervals. A fourth dose should be given at age 18 months unless poliomyelitis is endemic in the area, in which case the fourth dose is given 6 to 12 months after the third. Additional doses are recommended prior to school entry and then every 5 years until age 18.

See also: vaccine
References in periodicals archive ?
Diphtheria-tetanus-acellular pertussis and inactivated poliovirus vaccines given separately or combined for booster dosing at 4-6 years of age.
Sabin-IPV is an inactivated poliovirus vaccine derived from attenuated strains, and its safety and efficacy are expected to be comparable to the inactivated polio vaccines derived from virulent strains, which are commonly used outside Japan.
Inactivated poliovirus vaccine following oral poliovirus vaccine cessation.
The PPV and inactivated poliovirus vaccine can be administered either IM or subcutaneously (SQ), but most authorities recommend the IM route for PPV and the SQ route for 1PV.
Takeda Pharmaceutical Company Limited ( Takeda ) today announced the voluntary discontinuation of the development of TAK-361S, a four-component, combination Diptheria-Tetanus-acellular Pertussis (DTaP) and Sabin inactivated poliovirus vaccine (sIPV) that was in Phase 2 of clinical development.
In this single-blind, Phase II study, 609 infants were randomized 1:1 to receive either Hib-MenCY-TT or licensed Hib vaccine at 2, 4, and 6 months concomitantly with DTaP-Hep B-IPV (Pediarix[R] Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Hepatitis B [Recombinant] and Inactivated Poliovirus Vaccine Combined) and pneumococcal 7-valent conjugate vaccine (Prevnar[R] Pneumococcal 7-valent Conjugate Vaccine Diphtheria CRM Protein).
DTaP denotes pediatric dose of diphtheria toxoid and tetanus toxoid and acellular pertussis; vaccine (this formulation is preferred for all doses of the series); IPV, inactivated poliovirus vaccine (generally recommended for 2000); Hib, Haemophilus influenzae type b vaccine; MMR, measles-mumps-rubella combination vaccine; Td, adult does of diptheria toxoid and tetanus toxoid
During April 2016, the World Health Organization (WHO) coordinated global withdrawal of the type 2 component in oral poliovirus vaccine, replacing it with oral poliovirus vaccine containing only types 1 and 3, after introduction of inactivated poliovirus vaccine.
The ACIP, an advisory group of the Centers for Disease Control and Prevention, recommended a sequential schedule of 2 doses of inactivated poliovirus vaccine (IPV) followed by 2 doses of oral poliovirus vaccine (OPV), but also considered the all OPV or IPV schedules acceptable.
Complementing the switch from tOPV to bOPV, introduction of at least 1 dose of injectable, trivalent inactivated poliovirus vaccine (IPV) into childhood immunization schedules reduces risks from and facilitates responses to cVDPV2 outbreaks.